Literature DB >> 24562446

2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.

J Vansteenkiste1, L Crinò2, C Dooms1, J Y Douillard3, C Faivre-Finn4, E Lim5, G Rocco6, S Senan7, P Van Schil8, G Veronesi9, R Stahel10, S Peters11, E Felip12.   

Abstract

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on early-stage disease.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  ESMO; consensus; early disease; lung cancer; non-small-cell lung cancer

Mesh:

Year:  2014        PMID: 24562446     DOI: 10.1093/annonc/mdu089

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  126 in total

1.  Cons: long-term CT-scan follow-up is not the standard of care in patients curatively treated for an early stage non-small cell lung cancer.

Authors:  Jan P van Meerbeeck; Halil Sirimsi
Journal:  Transl Lung Cancer Res       Date:  2015-08

2.  Imaging texture analysis for automated prediction of lung cancer recurrence after stereotactic radiotherapy.

Authors:  Sarah A Mattonen; Shyama Tetar; David A Palma; Alexander V Louie; Suresh Senan; Aaron D Ward
Journal:  J Med Imaging (Bellingham)       Date:  2015-11-12

3.  Video-assisted thoracoscopic surgery right upper posterior segmentectomywith systemic mediastinal lymph node dissection.

Authors:  Lin Ma; Chengwu Liu; Lunxu Liu
Journal:  J Thorac Dis       Date:  2014-12       Impact factor: 2.895

4.  Stereotactic ablative body radiation therapy or surgery for operable early non-small cell lung cancer patients: bound hand and foot to evidence.

Authors:  Antonin Levy; Olaf Mercier; Cécile Le Péchoux
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

5.  Recommendations from the European Society of Thoracic Surgeons (ESTS) regarding computed tomography screening for lung cancer in Europe.

Authors:  Jesper Holst Pedersen; Witold Rzyman; Giulia Veronesi; Thomas A D'Amico; Paul Van Schil; Laureano Molins; Gilbert Massard; Gaetano Rocco
Journal:  Eur J Cardiothorac Surg       Date:  2017-03-01       Impact factor: 4.191

6.  SBRT versus lobectomy in stage I NSCLC: knowns, unknowns and its interpretation.

Authors:  Matthias Guckenberger
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

7.  Quality of Cancer Surveillance Clinical Practice Guidelines: Specificity and Consistency of Recommendations.

Authors:  Ryan P Merkow; Deborah Korenstein; Rubaya Yeahia; Peter B Bach; Shrujal S Baxi
Journal:  JAMA Intern Med       Date:  2017-05-01       Impact factor: 21.873

Review 8.  Salvage surgery after high-dose radiotherapy.

Authors:  Annemie Van Breussegem; Jeroen M Hendriks; Patrick Lauwers; Paul E Van Schil
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

Review 9.  Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?

Authors:  Lucio Buffoni; Tiziana Vavalà; Silvia Novello
Journal:  Curr Treat Options Oncol       Date:  2016-10

10.  Video-assisted thoracoscopic anatomic lung resections in Germany-a nationwide survey.

Authors:  Martin Reichert; Andrea Birgitta Gohlke; Florian Augustin; Dietmar Öfner; Andreas Hecker; Winfried Padberg; Johannes Bodner
Journal:  Langenbecks Arch Surg       Date:  2016-07-23       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.